Life Science Innovation: Who Should Pay?
Sometimes called “living drugs,” Cell and Gene Therapies have the potential to cure an individual of a rare disease by modifying that person’s genes. But due to the labor-intensive, individualized treatment, these drugs are expensive, to the tune of millions of dollars per patient.
Rena Conti, BU Questrom associate professor of markets, public policy, and law; U.S. Rep. Jake Auchincloss (D-Mass.); Michael Sherman, RA Capital Management venture partner; and Andrew Obenshain, biotech company Bluebird Bio CEO, discuss how to ensure continued innovation and access to gene and cell therapy without…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.